An open-label, dose-escalation study to assess the tolerability and pharmacokinetics of CB 189625 in healthy volunteers.
Phase of Trial: Phase I
Latest Information Update: 23 Jan 2013
At a glance
- Drugs CB 189625 (Primary)
- Indications Acute pain
- Focus Adverse reactions; Therapeutic Use
- 23 Jan 2013 Status changed from planning to recruiting.
- 11 Jan 2012 New trial record